CDT Environmental receives noncompliance letter from Nasdaq
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
J.P. Morgan Sticks to Its Hold Rating for SoFi (SOFI)
J.P. Morgan analyst Reginald Smith maintained a Hold rating on SoFi on July 30 and set a price target of $22.00. The company's shares closed yesterday at $21.23. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Smith is a 4-star analyst with an average return of 11.8% and a 51.00% success rate. Smith covers the Financial sector, focusing on stocks such as Riot Platforms, Marathon Digital Holdings, and Cleanspark. In addition to J.P. Morgan, SoFi also received a Hold from Redburn Atlantic's Harry Bartlett in a report issued yesterday. However, on July 31, Mizuho Securities maintained a Buy rating on SoFi (NASDAQ: SOFI). SOFI market cap is currently $25.17B and has a P/E ratio of 43.04. Based on the recent corporate insider activity of 60 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SOFI in relation to earlier this year. Most recently, in June 2025, Magdalena Yesil, a Director at SOFI sold 174,280.00 shares for a total of $2,469,547.60.
Business Insider
an hour ago
- Business Insider
J.P. Morgan Keeps Their Buy Rating on Merit Medical Systems (MMSI)
J.P. Morgan analyst Robbie Marcus maintained a Buy rating on Merit Medical Systems on July 31 and set a price target of $95.00. The company's shares closed yesterday at $84.78. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Marcus covers the Healthcare sector, focusing on stocks such as Medtronic, Edwards Lifesciences, and Baxter International. According to TipRanks, Marcus has an average return of 8.8% and a 52.81% success rate on recommended stocks. In addition to J.P. Morgan, Merit Medical Systems also received a Buy from Needham's Michael Matson in a report issued on July 31. However, yesterday, TR | OpenAI – 4o reiterated a Hold rating on Merit Medical Systems (NASDAQ: MMSI). The company has a one-year high of $111.45 and a one-year low of $81.04. Currently, Merit Medical Systems has an average volume of 657.7K. Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MMSI in relation to earlier this year. Most recently, in June 2025, Raul Jr. Parra, the CFO & Treasurer of MMSI sold 15,181.00 shares for a total of $1,423,218.75.
Yahoo
an hour ago
- Yahoo
GE HealthCare Technologies Second Quarter 2025 Earnings: EPS Beats Expectations
GE HealthCare Technologies (NASDAQ:GEHC) Second Quarter 2025 Results Key Financial Results Revenue: US$5.01b (up 3.5% from 2Q 2024). Net income: US$486.0m (up 14% from 2Q 2024). Profit margin: 9.7% (in line with 2Q 2024). EPS: US$1.06 (up from US$0.94 in 2Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period GE HealthCare Technologies EPS Beats Expectations Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 19%. Looking ahead, revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Performance of the American Medical Equipment industry. The company's shares are down 10.0% from a week ago. Valuation Our analysis of these results suggests GE HealthCare Technologies may be undervalued based on 6 important criteria we look at. To explore our complete evaluation click here and get an understanding of what analysts are thinking about the company's future. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
